Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Hepatitis C Virus | Current Treatment | EU5 | 2017

Login to access report north_east
Contact sales account_box

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA authorizations of Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), combined with Bristol-Myers Squibb’s Daklinza (daclatasvir) and AbbVie’s Viekirax +/- Exviera (ombitasvir/paritaprevir/ritonavir +/- dasabuvir), have ushered in the era of IFN-free therapy for chronic HCV and completely reshaped the HCV therapeutic market. Recent EMA approvals of Gilead’s Epclusa (sofosbuvir/velpatasvir) and Merck & Co’s Zepatier (elbasvir/grazoprevir) provide additional IFN-free options for EU5 HCV patients. Taken together, currently approved regimens provide efficacious IFN-free options for most HCV genotypes in the EU5. This research focuses on current and anticipated use of HCV regimens, including IFN-free and remaining IFN-based regimens, by capturing patient-share data, current prescribing trends, and anticipated changes in prescribing and treatment. We also evaluate physician-perceived drivers and obstacles to the uptake of key brands.

Questions Answered in This Report:

What factors influence physicians’ treatment and management of chronic HCV infections?

What are the major drug attributes driving physicians to prescribe certain brands?

What obstacles prevent physician prescribing of key HCV therapies?

How do physicians anticipate their prescribing of different therapies to change in the next six months?

Scope:

Markets covered: France, Germany, Italy, Spain, and United Kingdom

Methodology: Survey of 89 gastroenterologists and 162 hepatologists; approximately 50 respondents per EU5 country

Key drugs covered: Incivo, Victrelis, Sovaldi, Olysio, Daklinza, Harvoni, Viekirax + Exviera, Zepatier, Epclusa, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir

Key companies mentioned: AbbVie, Bristol-Myers Squibb, Gilead, Merck & Co., Janssen, Johnson & Johnson, Roche

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
north_east
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east